DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
86	肺動脈性肺高血圧症	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03016468 (ClinicalTrials.gov)	May 2017	6/1/2017	Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH	A Multicenter, 16-Week, Open-label Study Evaluating the Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Subjects With Pulmonary Arterial Hypertension	Pulmonary Arterial Hypertension	Drug: Parenteral Remodulin (treprostinil) injection;Drug: Oral Treprostinil	United Therapeutics	NULL	Withdrawn	18 Years	75 Years	All	0	Phase 2	NULL

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03016468
(ClinicalTrials.gov)

May 2017

6/1/2017

Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH

A Multicenter, 16-Week, Open-label Study Evaluating the Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Subjects With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Drug: Parenteral Remodulin (treprostinil) injection;Drug: Oral Treprostinil

United Therapeutics

NULL

Withdrawn

18 Years

75 Years

All

Phase 2

NULL